MSI Financial Services’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$995K Buy
27,440
+9,729
+55% +$388K 0.03% 448
2016
Q3
$815K Sell
17,711
-955
-5% -$49.8K 0.03% 498
2016
Q2
$938K Buy
18,666
+292
+2% +$15.5K 0.03% 418
2016
Q1
$983K Buy
18,374
+306
+2% +$18K 0.04% 381
2015
Q4
$1.19M Buy
18,068
+6,382
+55% +$394K 0.05% 319
2015
Q3
$660K Sell
11,686
-1,084
-8% -$70.3K 0.05% 335
2015
Q2
$755K Buy
12,770
+1,062
+9% +$65.5K 0.05% 358
2015
Q1
$729K Buy
11,708
+5,348
+84% +$311K 0.05% 378
2014
Q4
$366K Buy
6,360
+405
+7% +$22.6K 0.04% 428
2014
Q3
$320K Buy
5,955
+3,140
+112% +$166K 0.04% 450
2014
Q2
$148K Buy
2,815
+73
+3% +$3.73K 0.02% 654
2014
Q1
$145K Sell
2,742
-2,179
-44% -$101K 0.02% 638
2013
Q4
$197K Buy
4,921
+1,247
+34% +$49.1K 0.03% 500
2013
Q3
$139K Buy
3,674
+100
+3% +$3.9K 0.02% 558
2013
Q2
$140K Buy
+3,574
New +$139K 0.03% 515

Other funds holding TEVA

MSI Financial Services's TEVA Position: Q4 2016 in Review

MSI Financial Services increased its Teva Pharmaceuticals (TEVA) stake by 55% in Q4 2016, buying an estimated $388K and bringing the position to 27,440 shares worth $995K. The position accounts for 0.03% of the portfolio, ranked #448.

MSI Financial Services first reported a position in TEVA in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.19M in Q4 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • MSI Financial Services held 27,440 shares of Teva Pharmaceuticals worth $995K as of Q4 2016.
  • MSI Financial Services bought 9,729 Teva Pharmaceuticals shares in Q4 2016, an estimated $388K.
  • Teva Pharmaceuticals made up 0.03% of MSI Financial Services's portfolio in Q4 2016, its #448 holding.
  • MSI Financial Services first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • MSI Financial Services's Teva Pharmaceuticals position peaked at $1.19M in Q4 2015.
  • 737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on MSI Financial Services's 13F filing for Q4 2016, filed 13 Jan 2017.